close

Register today to unlock Valuecruncher and get unlimited access

  • Get unlimited access to all compartors and data
  • Save and share valuations as well as comment on others
  • Alter and save your favourite comparator companies

Already registered? Please login now

Comparison Analysis (switch to Discounted Cash Flow Analysis)
Dollar37Point57
Implied share price

Sell Overvalued by 47.2%

5% margin of safety What's this?

EV / EBITDA
Use Average
CELG
Celgene Corporation
DNA
Genentech, Inc.
Change
SNY
Sanofi SA (ADR)
Change
NVO
Novo Nordisk A/S (ADR)
Change
AMGN
Amgen, Inc.
Change
8.77 17.05 17.08 4.63 3.06 7.26
All amounts in millions
from last financial year
         
Implied Share Price $37.57 $50.35 $72.67 $359.03 $85.04
Market Cap 31,363 100,042 92,468 63,865 54,595
Net Debt -845 -3,369 11,280 -16,649 787
Enterprise Value (EV) 30,517 96,673 56,670 76,452 55,382
Revenue 4,842 13,418 35,058 66,346 15,582
EBITDA 1,789 5,661 12,249 24,983 7,627
Percent 37.0 % 42.2 % 34.9 % 37.7 % 48.9 %
EBIT 1,428 5,069 7,674 22,493 6,568
Percent 29.5 % 37.8 % 21.9 % 33.9 % 42.2 %
Balance Sheet          
Total Assets 10,005 21,787 100,165 64,698 48,871
Total Liabilities 4,493 6,116 43,946 27,250 29,842
Shareholders Equity 5,512 15,671 56,219 37,448 19,029.0

Comments

No comments yet. Login to comment.